134 related articles for article (PubMed ID: 7665249)
1. p53 mutations in ovarian tumors, detected by temperature-gradient gel electrophoresis, direct sequencing and immunohistochemistry.
Kappes S; Milde-Langosch K; Kressin P; Passlack B; Dockhorn-Dworniczak B; Röhlke P; Löning T
Int J Cancer; 1995 Feb; 64(1):52-9. PubMed ID: 7665249
[TBL] [Abstract][Full Text] [Related]
2. Alteration of the p53 tumor suppressor gene occurs independently of K-ras activation and more frequently in serous adenocarcinomas than in other common epithelial tumors of the human ovary.
Fujita M; Enomoto T; Inoue M; Tanizawa O; Ozaki M; Rice JM; Nomura T
Jpn J Cancer Res; 1994 Dec; 85(12):1247-56. PubMed ID: 7852189
[TBL] [Abstract][Full Text] [Related]
3. Genetic disparity between morphologically benign cysts contiguous to ovarian carcinomas and solitary cystadenomas.
Zheng J; Benedict WF; Xu HJ; Hu SX; Kim TM; Velicescu M; Wan M; Cofer KF; Dubeau L
J Natl Cancer Inst; 1995 Aug; 87(15):1146-53. PubMed ID: 7674319
[TBL] [Abstract][Full Text] [Related]
4. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms.
Teneriello MG; Ebina M; Linnoila RI; Henry M; Nash JD; Park RC; Birrer MJ
Cancer Res; 1993 Jul; 53(13):3103-8. PubMed ID: 8319218
[TBL] [Abstract][Full Text] [Related]
5. Quantitative analysis of follicle-stimulating hormone receptor in ovarian epithelial tumors: a novel approach to explain the field effect of ovarian cancer development in secondary mullerian systems.
Wang J; Lin L; Parkash V; Schwartz PE; Lauchlan SC; Zheng W
Int J Cancer; 2003 Jan; 103(3):328-34. PubMed ID: 12471615
[TBL] [Abstract][Full Text] [Related]
6. High incidence of p53 gene mutation in human ovarian cancer and its association with nuclear accumulation of p53 protein and tumor DNA aneuploidy.
Kihana T; Tsuda H; Teshima S; Okada S; Matsuura S; Hirohashi S
Jpn J Cancer Res; 1992 Sep; 83(9):978-84. PubMed ID: 1429209
[TBL] [Abstract][Full Text] [Related]
7. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis.
Dehari R; Kurman RJ; Logani S; Shih IeM
Am J Surg Pathol; 2007 Jul; 31(7):1007-12. PubMed ID: 17592266
[TBL] [Abstract][Full Text] [Related]
8. Two types of primary mucinous ovarian tumors can be distinguished based on their origin.
Simons M; Simmer F; Bulten J; Ligtenberg MJ; Hollema H; van Vliet S; de Voer RM; Kamping EJ; van Essen DF; Ylstra B; Schwartz LE; Wang Y; Massuger LF; Nagtegaal ID; Kurman RJ
Mod Pathol; 2020 Apr; 33(4):722-733. PubMed ID: 31695154
[TBL] [Abstract][Full Text] [Related]
9. p53 gene mutations and protein accumulation in human ovarian cancer.
Kupryjańczyk J; Thor AD; Beauchamp R; Merritt V; Edgerton SM; Bell DA; Yandell DW
Proc Natl Acad Sci U S A; 1993 Jun; 90(11):4961-5. PubMed ID: 8506342
[TBL] [Abstract][Full Text] [Related]
10. p53 mutation in epithelial ovarian carcinoma and borderline ovarian tumor.
Lee JH; Kang YS; Park SY; Kim BG; Lee ED; Lee KH; Park KB; Kavanagh JJ; Wharton JT
Cancer Genet Cytogenet; 1995 Nov; 85(1):43-50. PubMed ID: 8536236
[TBL] [Abstract][Full Text] [Related]
11. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
12. p53 mutation in carcinomas arising in ovarian cystic teratomas.
Fujii T; Oguni S; Kikuchi M; Kanai N; Saito K
Pathol Int; 1995 Sep; 45(9):649-54. PubMed ID: 8548037
[TBL] [Abstract][Full Text] [Related]
13. [Overexpression and prognostic value of p53 and HER2/neu proteins in benign ovarian tissue and in ovarian cancer].
Coronado Martín PJ; Fasero Laiz M; García Santos J; Ramírez Mena M; Vidart Aragón JA
Med Clin (Barc); 2007 Jan; 128(1):1-6. PubMed ID: 17266884
[TBL] [Abstract][Full Text] [Related]
14. Is it possible to diagnose malignancy from fluid in cystic ovarian tumors?
Yamada R; Maeda N; Oguri H; Adachi Y; Takeuchi T; Furihata M; Fukaya T
Eur J Obstet Gynecol Reprod Biol; 2013 Nov; 171(1):96-100. PubMed ID: 24017961
[TBL] [Abstract][Full Text] [Related]
15. K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary.
Enomoto T; Weghorst CM; Inoue M; Tanizawa O; Rice JM
Am J Pathol; 1991 Oct; 139(4):777-85. PubMed ID: 1656759
[TBL] [Abstract][Full Text] [Related]
16. [Expression P53 protein and chromosome aberrations in benign tumors and ovarian carcinoma].
Kamiński K; Putowski L; Oleszczuk J
Ginekol Pol; 2003 Sep; 74(9):741-5. PubMed ID: 14674118
[TBL] [Abstract][Full Text] [Related]
17. Aberrant hypermethylation of RASSF1A promoter in ovarian borderline tumors and carcinomas.
Choi YL; Kang SY; Shin YK; Choi JS; Kim SH; Lee SJ; Bae DS; Ahn G
Virchows Arch; 2006 Mar; 448(3):331-6. PubMed ID: 16315018
[TBL] [Abstract][Full Text] [Related]
18. Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors.
Ortiz BH; Ailawadi M; Colitti C; Muto MG; Deavers M; Silva EG; Berkowitz RS; Mok SC; Gershenson DM
Cancer Res; 2001 Oct; 61(19):7264-7. PubMed ID: 11585764
[TBL] [Abstract][Full Text] [Related]
19. p53 expression in ovarian borderline tumors and stage I carcinomas.
Kupryjańczyk J; Bell DA; Yandell DW; Scully RE; Thor AD
Am J Clin Pathol; 1994 Nov; 102(5):671-6. PubMed ID: 7942635
[TBL] [Abstract][Full Text] [Related]
20. Discordance in p53 mutations when comparing ascites and solid tumors from patients with serous ovarian cancer.
Provencher DM; Lounis H; Fink D; Drouin P; Mes-Masson AM
Tumour Biol; 1997; 18(3):167-74. PubMed ID: 9143413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
